In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AMO Pharma Ltd.

www.amo-pharma.com

Latest From AMO Pharma Ltd.

Pipeline Watch: Top-Line Phase III Results For Esketamine, ALKS-5461 And Quizartinib

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Approvals Pipeline Watch

Pipeline Watch: Phase III Starts With Oxabact, Imeglimin And Favipiravir

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

 

Pipeline Watch Approvals

Pipeline Watch: Phase III Progress With Esaxerenone, Lusutrombopag

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Deal Watch: Takeda Continues Transaction Spree With Four More Deals

Takeda's recent deals include a license in Asian for Tesaro's PARP inhibitor Zejula. Meanwhile, Japanese rival Mitsubishi Tanabe is paying roughly $1bn to acquire Israel's NeuroDerm.

Commercial Deals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • AMO Pharma Ltd.
  • Senior Management
  • Michael Snape, PhD, CEO, CSO
    Marytn Williams, CFO
    Joseph Horrigan, MD, CMO
    Alison McMorn, PhD, VP, Clin. Dev.
  • Contact Info
  • AMO Pharma Ltd.
    Phone: +44 1483 319070
    152-160 City Rd.
    Kemp House
    London, EC1V 2NX
    UK
UsernamePublicRestriction

Register